The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.

Breast cancer patients in England and Wales will not have access to the drug after pricing negotiations failed between NICE and drugmakers.

The company expects the trial to support the submission of a biologics license application with the US Food and Drug Administration in 2026.

The firm is paying €7 million to add fibroblast activation protein-targeting assets to its pipeline, which it will initially develop for bladder cancer.

In the trial, researchers will test how well Medera's SRD-001 gene therapy improves symptoms in heart failure patients with reduced ejection fraction.